Combining Behavioral Treatment With Agonist Maintenance - 1

This study is ongoing, but not recruiting participants.

First Received: September 20, 1999 Last Updated: October 27, 2008 History of Changes

Sponsor:	National Institute on Drug Abuse (NIDA)
Collaborator:	Yale University
Information provided by:	National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:	NCT00000311

Purpose

The purpose of this study is to evaluate whether the community reinforcement approach (CRA) plus contingency management (CM) is more effective overall than CRA only in reducing illicit opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up after completion of study protocol, and to compare the efficacy of maintenance on buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM.

Condition	Intervention	Phase
Cocaine-Related Disorders Opioid-Related Disorders Substance-Related Disorders	Drug: Buprenorphine	Phase III

Study Type:	Interventional
Study Design:	Treatment
Official Title:	Combining Behavioral Treatment With Agonist Maintenance

Resource links provided by NLM:

Drug Information available for: Buprenorphine Buprenorphine hydrochloride

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:

Depression
Withdrawal symptoms
Opioid and cocaine use
Social and psychological functioning
AIDS risk behavior

Estimated Enrollment:	168
Study Start Date:	September 1999

Arms	Assigned Interventions
1: Experimental Therapeutic Contracting (TC)	Drug: Buprenorphine Experimental Therapeutic Contracting (TC) Experimental Cognitive Behavioral Coping Skills Therapy (CBT)
2: Experimental Cognitive Behavioral Coping Skills Therapy (CBT)	Drug: Buprenorphine Experimental Therapeutic Contracting (TC) Experimental Cognitive Behavioral Coping Skills Therapy (CBT)

Eligibility

Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Please contact site for information.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000311

Locations

United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519

Sponsors and Collaborators

National Institute on Drug Abuse (NIDA)

Yale University

Investigators

Principal Investigator:

Richard Schottenfeld, M.D.

Yale University

More Information

No publications provided

Responsible Party:	Yale University School of Medicine ( Richard S. Schottenfeld, MD )
Study ID Numbers:	NIDA-09413-1, R01-09413-1
Study First Received:	September 20, 1999
Last Updated:	October 27, 2008
ClinicalTrials.gov Identifier:	NCT00000311 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Cocaine-Related Disorders
Disease
Narcotic Antagonists
Physiological Effects of Drugs
Central Nervous System Depressants
Disorders of Environmental Origin
Narcotics
Opioid-Related Disorders
Pharmacologic Actions
Buprenorphine

Pathologic Processes
Mental Disorders
Sensory System Agents
Therapeutic Uses
Substance-Related Disorders
Analgesics
Peripheral Nervous System Agents
Central Nervous System Agents
Analgesics, Opioid

ClinicalTrials.gov processed this record on November 09, 2009